These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 15814016)

  • 1. Colorectal cancer screening in Finland: details of the national screening programme implemented in Autumn 2004.
    Malila N; Anttila A; Hakama M
    J Med Screen; 2005; 12(1):28-32. PubMed ID: 15814016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of colorectal cancer screening in Finland: experiences from the first three years of a public health programme.
    Malila N; Oivanen T; Hakama M
    Z Gastroenterol; 2008 Apr; 46 Suppl 1():S25-8. PubMed ID: 18368636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coverage and performance of colorectal cancer screening with the faecal occult blood test in Finland.
    Malila N; Palva T; Malminiemi O; Paimela H; Anttila A; Hakulinen T; Järvinen H; Kotisaari ML; Pikkarainen P; Rautalahti M; Sankila R; Vertio H; Hakama M
    J Med Screen; 2011; 18(1):18-23. PubMed ID: 21536812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recommendations on population screening for colorectal cancer in New Zealand. Members of the National Health Committee Working Party on Population Screening for Colorectal Cancer.
    N Z Med J; 1999 Jan; 112(1080):4-6. PubMed ID: 10073156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A 25-year follow-up of a population screened with faecal occult blood test in Finland.
    Malila N; Hakama M; Pukkala E
    Acta Oncol; 2007; 46(8):1103-6. PubMed ID: 17851857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The immunochemical faecal occult blood test leads to higher compliance than the guaiac for colorectal cancer screening programmes: a cluster randomized controlled trial.
    Federici A; Giorgi Rossi P; Borgia P; Bartolozzi F; Farchi S; Gausticchi G
    J Med Screen; 2005; 12(2):83-8. PubMed ID: 15949119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Randomized controlled trial of sequence mass screening program for colorectal cancer].
    Liu X; Zheng S; Chen K; Ma X; Zhou L; Yu H; Yao K; Chen K; Cai S; Zhang S
    Zhonghua Liu Xing Bing Xue Za Zhi; 2000 Dec; 21(6):430-3. PubMed ID: 11860828
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential impact of population-based colorectal cancer screening in Canada.
    Flanagan WM; Le Petit C; Berthelot JM; White KJ; Coombs BA; Jones-McLean E
    Chronic Dis Can; 2003; 24(4):81-8. PubMed ID: 14733756
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lessons learnt from a population-based pilot programme for colorectal cancer screening in Catalonia (Spain).
    Peris M; Espinàs JA; Muñoz L; Navarro M; Binefa G; Borràs JM;
    J Med Screen; 2007; 14(2):81-6. PubMed ID: 17626707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Arguments against implementing a population-based screening programme for colorectal cancer].
    Bonneux L
    Ned Tijdschr Geneeskd; 2008 Aug; 152(32):1777. PubMed ID: 18754310
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From screening criteria to colorectal cancer screening: what can New Zealand learn from other countries?
    Shaw C; Cunningham R; Sarfati D
    N Z Med J; 2008 Aug; 121(1279):84-95. PubMed ID: 18709051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Faecal occult blood test-based screening programme with high compliance for colonoscopy has a strong clinical impact on colorectal cancer.
    Parente F; Marino B; DeVecchi N; Moretti R; ; Ucci G; Tricomi P; Armellino A; Redaelli L; Bargiggia S; Cristofori E; Masala E; Tortorella F; Gattinoni A; Odinolfi F; Pirola ME
    Br J Surg; 2009 May; 96(5):533-40. PubMed ID: 19358181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Many participants in fecal occult blood test population screening have a higher-than-average risk for colorectal cancer.
    Worthley DL; Smith A; Bampton PA; Cole SR; Young GP
    Eur J Gastroenterol Hepatol; 2006 Oct; 18(10):1079-83. PubMed ID: 16957514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Measuring the quality of colorectal cancer screening: the importance of follow-up.
    Etzioni DA; Yano EM; Rubenstein LV; Lee ML; Ko CY; Brook RH; Parkerton PH; Asch SM
    Dis Colon Rectum; 2006 Jul; 49(7):1002-10. PubMed ID: 16673056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Medications with anticoagulant properties increase the likelihood of a negative colonoscopy in faecal occult blood test population screening.
    Clarke P; Jack F; Carey FA; Steele RJ
    Colorectal Dis; 2006 Jun; 8(5):389-92. PubMed ID: 16684082
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colorectal cancer screening with faecal occult blood test within a multiple disease screening programme: an experience from Keelung, Taiwan.
    Yang KC; Liao CS; Chiu YH; Yen AM; Chen TH
    J Med Screen; 2006; 13 Suppl 1():S8-13. PubMed ID: 17227635
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The screening of sporadic colorectal cancer].
    Zavoral M
    Vnitr Lek; 2004 Oct; 50 Suppl 1():S103-6. PubMed ID: 15651152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Colorectal cancer screening: immunological test for faecal occult blood preferred].
    Jansen JB; van Rossum LG; Laheij RJ
    Ned Tijdschr Geneeskd; 2009; 153():A474. PubMed ID: 19785842
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for colorectal cancer.
    Hakama M; Hoff G; Kronborg O; Påhlman L
    Acta Oncol; 2005; 44(5):425-39. PubMed ID: 16118076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for colorectal cancer: a general-practice-based study.
    Marjoram J; Strachan R; Allan A; Allan E
    Br J Gen Pract; 1996 May; 46(406):283-86. PubMed ID: 8762743
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.